Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme

被引:24
|
作者
Onishi, Manabu [1 ]
Kurozumi, Kazuhiko [1 ]
Ichikawa, Tomotsugu [1 ]
Date, Isao [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama 7008558, Japan
关键词
cilengitide; bevacizumab; angiogenesis; invasion; GELATINASE-B MMP-9; BRAIN-TUMORS; INTEGRIN ALPHA(V)BETA(3); RECURRENT GLIOBLASTOMA; ENDOTHELIAL-CELLS; MALIGNANT GLIOMAS; SINGLE-AGENT; PHASE-II; IN-VIVO; CILENGITIDE;
D O I
10.2176/nmc.ra2013-0200
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Despite advances in surgical and medical therapy, glioblastoma multiforme (GBM) remains a fatal disease. There has been no significant increase in survival for patients with this disease over the last 20 years. Tumor vasculature formation and glioma cell invasion along the white matter tracts both play a pivotal role in glioma development. Angiogenesis and invasion are the major factors believed to be responsible for treatment resistance in tumors, and a better understanding of the glioma invasion and angiogenesis mechanisms will lead to the development of potential new treatments. In this review, we focus on the molecular characteristics of angiogenesis and invasion in human malignant glioma. We discuss bevacizumab and cilengitide, which are used to inhibit angiogenesis in GBM.
引用
收藏
页码:755 / 763
页数:9
相关论文
共 50 条
  • [31] Development of anti-angiogenic, anti-tumor peptidomimetics of anginex
    Dings, Ruud P. M.
    Heun, Hanke
    Hoye, Tom R.
    Griffioen, Arjan W.
    Mayo, Kevin H.
    CANCER RESEARCH, 2006, 66 (08)
  • [32] Interaction between tumor metabolism and anti-angiogenic therapy
    Indraccolo, S.
    ACTA PHYSIOLOGICA, 2014, 210 : 16 - 16
  • [33] Role of the tumor stroma in resistance to anti-angiogenic therapy
    Huijbers, Elisabeth J. M.
    van Beijnum, Judy R.
    Thijssen, Victor L.
    Sabrkhany, Siamack
    Nowak-Sliwinska, Patrycja
    Griffioen, Arjan W.
    DRUG RESISTANCE UPDATES, 2016, 25 : 26 - 37
  • [34] Regulators of angiogenesis as targets for anti-angiogenic tumor therapy
    Breier, G
    Heidenreich, R
    Gaumann, A
    Groot, M
    Licht, A
    Nicolaus, A
    Schmitz, J
    Reichmann, E
    Plate, KH
    Vajkoczy, P
    ANNALS OF HEMATOLOGY, 2002, 81 : S71 - S72
  • [35] VEGF ISOFORMS AS OUTCOME BIOMARKER FOR ANTI-ANGIOGENIC THERAPY IN RECURRENT GLIOBLASTOMA
    D'Alessandris, Quintino Giorgio
    Martini, Maurizio
    Cenci, Tonia
    Capo, Gabriele
    Ricci-Vitiani, Lucia
    Larocca, Luigi Maria
    Pallini, Roberto
    NEUROLOGY, 2015, 84 (18) : 1906 - 1908
  • [36] Gene expression changes underlying glioblastoma resistance to anti-angiogenic therapy
    Chen, William C.
    Jahangiri, Arman
    Yagnik, Garima
    Sidorov, Maxim
    Rick, Jonathan
    Kuang, Ruby
    DeLay, Michael
    Aghi, Manish K.
    CANCER RESEARCH, 2016, 76
  • [37] Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms
    Jo, Mi-Young
    Kim, Young Gyu
    Kim, Yonghyun
    Lee, Se Jeong
    Kim, Mi Hyun
    Joo, Kyeung Min
    Kim, Hyeon Ho
    Nam, Do-Hyun
    MOLECULAR MEDICINE REPORTS, 2012, 6 (01) : 88 - 92
  • [38] New frontiers in the development of anti-angiogenic therapy for endometriosis
    Tayade, C.
    PLACENTA, 2013, 34 (02) : A83 - A83
  • [39] Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model
    Masahiro Maeyama
    Kazuhiro Tanaka
    Masamitsu Nishihara
    Yasuhiro Irino
    Masakazu Shinohara
    Hiroaki Nagashima
    Hirotomo Tanaka
    Satoshi Nakamizo
    Mitsuru Hashiguchi
    Yuichi Fujita
    Masaaki Kohta
    Eiji Kohmura
    Takashi Sasayama
    Scientific Reports, 11
  • [40] Development of lentiviral vectors for anti-angiogenic gene therapy
    Tai, CK
    Shichinohe, T
    Nishida, M
    Hegerich-Gilliam, S
    Bochner, BH
    Kasahara, N
    CANCER GENE THERAPY, 2000, 7 (12) : S15 - S15